Human Embryonic Stem Cells Market is forecast to reach a value of US$ 1,955.3 Mn by 2028 at a CAGR of 9.2% between 2022 and 2028 | Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA

Because human embryonic stem cells (hESCs) are pluripotent, they have the ability to develop into any type of cell in the body. They are created from blastocysts, which are very young human embryonic cells. Pluripotent cells called embryonic stem cells (ESC) give rise to all somatic cell types in the developing embryo. Human embryonic stem cells have a significant therapeutic potential and have the potential to replace current standards of care for a number of cardiac and cancerous disorders. In many nations, using human embryos for ES cell research is currently a hot topic on the ethical and political agenda.

Market Statistics

By the end of 2021, the global market for human embryonic stem cells is anticipated to reach US$ 1,152.2 million.

To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5275

Drivers

During the projected period, favourable government initiatives and growing public support for stem cell research are anticipated to drive market expansion for human embryonic stem cells worldwide. Due to the significant potential for use in treatment and the possibility for hESCs to become the standard of care for a variety of cardiac and malignant disorders, government and commercial organisations from all over the world are funding stem cell research through national funding bodies. The Australian government provided $5.9 million in funding in June 2020 for eight medical research initiatives to discover fresh, ground-breaking stem cell therapies for fatal illnesses like leukaemia, Parkinson’s disease, and epilepsy.

Opportunities

Players in the human embryonic stem cell market should have tremendous development prospects due to the increasing demand for regenerative treatments around the globe. For instance, hESC holds enormous potential for regenerative medicine and may help treat a variety of serious human diseases, including diabetes, myocardial infarction, stroke, and brain diseases. In April 2022, TreeFrog Therapeutics, a biotechnology company working to develop cell therapies based on induced pluripotent stem cells (iPSCs) that are safer, more effective, and more reasonably priced, announced the creation of The Stem Cell SpaceShot Grant, a $100,000 research grant in the area of stem cell biology and regenerative medicine.

Restraints

Significant barriers to commercial expansion for human embryonic stem cells are likely to include high treatment costs and strict regulatory requirements. The price of stem cell therapy might range from US$ 5000 to US$ 50,000. Even more expensive is the cost of the media used in the production of human embryonic stem cells. Just 500ml of Thermo Fischer medium cost about INR 32,954. To perform any kind of stem cell clinical trial in India, you must first obtain the Drugs Control General of India.

Impact

The COVID-19 outbreak has benefited the expansion of the global market for human embryonic stem cells. This is due to the expanding use of stem cell treatments and the increase in clinical trials conducted globally. To combat the pandemic, a lot of governments, pharmaceutical and biotech companies, and research organisations are concentrating on creating or releasing safe and effective medications or vaccinations. For instance, Lineage Cell Therapeutics was awarded a US$ 5 million grant from the California Institute for Regenerative Medicine (CIRM) in May 2020 to support the use of VAC, Lineage’s allogeneic dendritic cell therapy, for the creation of a potential vaccine against COVID-19, the virus that is caused by SARS-CoV-2.

Key Takeaways

The market for human embryonic stem cells was estimated at US$ 1,058.9 million in 2021 and is anticipated to grow at a CAGR of 9.2% from 2022 to 2028 to reach US$ 1,955.3 million.

Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5275

Regenerative medicine held a dominant position among applications in the global market for human embryonic stem cells in 2021, accounting for 60.4% of the market’s value share. Increasing approval and the introduction of new products are anticipated to fuel the segment’s growth over the course of the forecast period.

Industry Trends

Different stem cell types are applied in therapeutic settings. Numerous pharma and biopharma businesses across the world are actively investigating these cells due to their numerous potential uses at the clinical stage for treating a variety of ailments. Additionally, the number of clinical trials is growing globally as a result of the success of human embryonic stem cells and technological developments in the stem cell field. During the projected period, it is anticipated that this tendency will continue, fueling the market for human embryonic stem cells.

Competitive Landscape

Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc. are a few of the major companies active in the global market for human embryonic stem cells.

Recent Developments

PromoCell said in August 2019 that it is now supplying a wide variety of high-quality HLA-typed cells from various organs, enabling researchers to test their treatments and look for potential interactions.

The definitive agreement under which Thermo Fisher Scientific Inc. will acquire Brammer Bio was announced by both parties in April 2019

Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/5275